A ccurate staging of lymph node involvement is a critical aspect of the initial management of patients with nonmetastatic non-small cell lung cancer (NSCLC) that influences decisions about the appropriateness and timing of surgery, radiation, and systemic therapy. Since the lung cancer staging system was first developed in 1973, 1 lymph node involvement has been categorized as N0 (no nodes involved), N1 (peribronchial, interlobar, or perihilar lymph nodes involved), N2 (ipsilateral mediastinal nodes involved), or N3 (contralateral mediastinal or supraclavicular nodes involved). The classification of these N descriptors into the overall tumor stages of I through III has been used to predict outcomes and to assist in treatment selection. During the past 20 years, numerous studies have evaluated the validity of the N descriptors and have suggested that these could be refined to provide more accurate prognostic stratification by subdividing them either according to specific anatomical locations (e.g., N1 peribronchial versus N1 perihilar) or the number of involved lymph nodes (e.g., single versus multiple N2 nodes). This study was undertaken as part of the effort by the staging committee of the International Association for the Study of Lung Cancer (IASLC) to determine whether the current international lung cancer staging system required revision in preparation for the seventh edition of the Union Internationale Contre le Cancer (UICC) and American Joint Commission on Cancer (AJCC) cancer staging manuals. We sought to define whether the current N descriptors for NSCLC should be maintained or revised.
METHODS

Data Acquisition and Analysis
The process for the development of the IASLC lung database has been described previously. 28 Briefly, the database was developed through an international consortium of institutions and clinical trials groups that submitted staging and outcomes data on a total of 100,869 lung cancer cases managed within the time frame of 1990 to 2000. Data were collected retrospectively from 47 preexisting databases, which varied widely in terms of the levels of detail provided. Data management and statistical analyses were provided by coinvestigators at Cancer Research and Biostatistics in Seattle, Washington. Of the 81,015 lung cancer patients and the 67,725 NSCLC patients who met the initial screening requirements of a complete set of tumor, node, metastasis (TNM) by either clinical or pathological staging, known histological type, and survival follow-up, 38,265 patients with no clinical evidence of metastatic disease (cM0) had information on clinical N staging (cN), and 28,371 surgically managed patients provided information on pathologic N staging (pN). Clinical staging included all tests and imaging studies done for initial extent-of-disease evaluation and information obtained from mediastinoscopy, but not from thoracotomy. Positron emission tomography (PET) was not in widespread use internationally during the time frame of this study, so PET data for clinical staging were not available. Pathological staging included all of the information available from clinical staging plus the pathological information from specimens obtained at thoracotomy. Twelve of the 47 databases submitted to the project included data on sampling results (positive, negative, not done) for individual nodal stations. Further analyses of overall survival in relation to subsets of pN1 and pN2 stages were performed for 2876 patients who underwent R0 (microscopically complete) resection without induction therapy and who successfully met logic checks of pN stage for data accuracy (pN stage in relation to highest positive nodal station recorded). Of these, 1721 cases (60%) were submitted from Japan, 701 cases (24%) came from Europe, 380 (13.2%) were from North America, and 74 (2.6%) were from Australia or Taiwan. The minimum lymph node stations for which documentation was available from all contributing groups included nodal level 2 and levels 4 through 9. All but one group provided documentation for levels 11 and 12, and most groups provided documentation for supraclavicular lymph nodes and nodes at levels 1, 13, and 14. Documentation of level 3 nodes was available from half of the contributing groups.
Surgical cases from Japan were staged according to the Naruke lymph node map, adopted by the Japan Lung Cancer Society as the official staging map (Figure 1) . 29 Those from all other countries were staged according to the MountainDresler modification of the American Thoracic Society (MD-ATS) map (Figure 2 ). 30 -32 From the perspective of grouping lymph node stations into N1 versus N2 categories, the main discrepancy between these two lymph node maps is that the Naruke map considers lymph nodes in the subcarinal space along the inferior border of the mainstem bronchus to be station 10 (hence, N1), whereas these are labeled as level 7 (and, therefore, N2) in the MD-ATS map. Within the context of a retrospective analysis, there was no way to reconcile this inherent difference in the designation of subcarinal lymph nodes. A lesser discrepancy between these two maps occurs in the labeling of lymph nodes from the right paratracheal region. Lymph nodes located between the right main pulmonary artery and the origin of the innominate artery are labeled as right level 4 (R4) in the MD-ATS map, whereas in the Naruke map the upper half of this region is considered level 2 (R2), and only the nodes located between the right main pulmonary artery and the superior border of the azygos vein are considered 4R. Nevertheless, all of these lymph nodes would be considered N2 according to either mapping system. This difference in nomenclature introduces an irreconcilable but likely small discrepancy in data analysis (Table 1) .
Statistical Methodology
Survival was measured from the date of entry (date of diagnosis for registries, date of registration for protocols) for clinically staged data and from the date of surgery for pathologically staged data; it was calculated by the KaplanMeier method. Prognostic groups were assessed by Cox regression analysis, using the SAS System for Windows version 9.0 PHREG procedure.
RESULTS
Overall Survival According to Clinical N Staging
The overall survival by cN staging for all 38,265 cM0 (any T stage) patients is shown in Figure 3 . These survival curves show clear differences in outcome for each of the cN categories. Additional analyses indicate that these differences in outcome occurred predominantly among the clinically staged patients who underwent surgical treatment. For the clinically staged cM0 patients who were managed nonsurgically (n ϭ 15,451), the median and 5-year survival rates ranged, respectively, from 13 months and 9% for N0 to 9 months and 5% for N3 disease (data not shown). Whether the absence of survival differences for patients managed nonsurgically reflects the lack of efficacy of available treatment, the influence of medical comorbidities, or both, cannot be determined from this database.
Overall Survival According to Pathological N Staging
The overall survival by pN staging for the 28,371 cM0 (any T stage) patients who were managed surgically (and who had no evidence of intrathoracic M1 disease at thoracotomy) is shown in Figure 4 . These survival curves again show significant differences in outcome for each of the pN categories. Figure 4 also shows the survival rates for surgically managed patients for whom cN staging information was available (n ϭ 22,814), again indicating distinct differences in outcome for each N category.
Comparison of the survival rates by cN and pN indicates that the additional information provided from pathological staging defines a group of N0 stage tumors with better survival and a group of N3 stage tumors with worse survival than expected from clinical staging alone.
Relationships between the Site of the Primary Tumor and the Presence of Lymph Node Metastases
Information on the site of the primary tumor in relationship to the presence of lymph node metastases (pN) was available from 2538 N1 and N2 cases. There were slightly more upper-lobe (n ϭ 1385; 56%) than lower-lobe tumors. The upper-lobe tumors were associated with the highest frequency of N1 (n ϭ 551; 53%) and N2 (59%) nodal metastases. The right middle lobe was the least common primary tumor site. Among the primary tumors that had only a single involved N2 lymph node station, the most common site of lymph node metastases was level 4R for right upperlobe tumors (191/280; 68%), levels 5/6 for left upper-lobe tumors (195/251; 78%), and level 7 for middle-and lowerlobe tumors (228/353; 65%). 
Survival in Relationship to the Extent of N1 and N2 Disease in Cases with pN Staging
Exploratory analyses were performed to determine whether, in patients with pN staging, survival was influenced by the anatomical location of involved lymph nodes, by the presence of "skip metastases" (N2 disease in the absence of N1), or by the number of involved lymph node stations. The 522 N1 cases with involvement of peribronchial levels 12 to 14 were evaluated to determine whether survival was influenced by involvement of the peribronchial (levels 12-14) (Table 2a) , apart from the general finding that survivorship decreased as the number of positive stations increased. To reconcile the Naruke and MD-ATS lymph node maps and to permit analyses of cases with N1 and, especially, N2 disease to include larger numbers of patients, lymph node stations were grouped together into anatomical "zones." Lymph nodes at levels 1 through 4 were grouped together into the upper zone, levels 5 and 6 into the aortopulmonary (AP) zone, level 7 into the subcarinal zone, levels 8 and 9 into the lower zone, levels 10 and 11 into the hilar zone, and levels 12 to 14 into the peripheral zone (Figure 2) . The appropriateness of grouping lymph node stations into zones was suggested by exploratory analyses that failed to identify significant differences in survival in relation to disease in all of the various N1 and N2 lymph node stations in the data submitted from Japan, from non-Japanese groups, or both (data not shown). As shown in Table 2b , significant differences in survival for patients with lymph node metastases confined to a single zone were seen only for cases of rightsided tumors with upper-or subcarinal zone disease compared with peripheral zone metastases. No differences in survival were identified among patients who had single-zone N2 disease.
Potential differences in survival were analyzed for cases with skip metastases, focusing on upper-lobe tumors, which are thought to be most frequently associated with these. AP zone disease in the absence of N1 metastases was associated with a better survival rate in patients with left upper-lobe tumors, but similar differences in survival were not identified for right upper-lobe tumors with right paratracheal nodal metastases (Table 2c) .
The potential impact of the number of involved lymph node zones on survival was then examined. As can be seen in Figure 5 , three groups were found to have significantly different survival rates: patients who had N1 single-zone disease, those who had either multiple N1 or single N2 zone metastases, and those who had multiple N2 lymph node zones involved. These prognostically distinct groups suggested that it might be appropriate to subdivide the current N staging descriptors into N1a (single N1 zone), N1b (multiple N1 zones), N2a (single N2 zone), and N2b (multiple N2 zones). To determine whether such a revision to the staging system should be considered, these additional N categories were analyzed in conjunction with each T stage category (e.g., T1N1a, T1N1b, T1N2a, T1N2b, etc.) rather than across all T stages, as was done for all of the preceding analyses. Nevertheless, the number of patients available in each of these subsets was too small to yield statistically valid analyses. Therefore, on the basis of the available data, we cannot recommend altering the current N stage descriptors.
DISCUSSION
Accurate staging of lymph node involvement has long been recognized as a key aspect of the initial management of NSCLC that helps in selecting treatment and predicting outcome. In patients undergoing surgery for possible resection of NSCLC, careful assessment of potential nodal disease has gradually become an accepted part of the operation since Cahan first described radical mediastinal lymph node dissection in the early 1950s. 1, 33 For similar reasons, mediastinoscopy and imaging studies such as CT (computed tomography) and PET scanning have become standard components of the initial clinical staging of NSCLC. 31 The development of the Naruke and, subsequently, of the ATS lymph node maps, provided standard nomenclature used by all clinicians and pathologists involved in the care of NSCLC patients to assist in uniform N staging. Traditionally, these maps labeled N2 or N3 nodes with single-digit numbers (nodal stations 1-9) and N1 nodes with double-digit numbers (nodal stations 10 -14) . From the inception of the AJCC and UICC lung cancer staging systems in 1973, the N0, N1, N2, and N3 descriptors were used to help establish stage classifications for both clinical and pathological staging. The fifth edition of the lung cancer staging system, based on a database developed by Dr. Clifton Mountain of 5319 cases (4351 patients treated at the MD Anderson Cancer Center, and 968 from other North American centers), led to a revision of the stage classifications but maintained the existing distinctions among the N descriptors. 34 In the absence of compelling alternative data, no changes were made to the sixth edition of the AJCC and UICC staging system. The current IASLC database includes a much larger number of cases from databases around the world on which to test the validity of the current staging system. Our data show that the N0, N1, N2, and N3 descriptors, whether derived from clinical or pathological staging, clearly identify prognostically distinct groups of patients, and it is therefore appropriate to maintain these descriptors in the upcoming seventh version of the lung cancer staging system. Notably, the IASLC database is the first international database that has shown these descriptors to have internal and external validity.
During the past 25 years, numerous studies have examined the patterns of lymphatic drainage of the lung and have analyzed the influence of N1 and N2 lymph node involvement on overall survival. These series are retrospective, are based on pathological staging, and include relatively small numbers of patients. Among patients undergoing surgery for NSCLC, our data corroborate the findings of other studies, including a higher frequency of upper-lobe tumors and a predominance of lymphatic drainage to the superior mediastinum for right upper-lobe tumors, to the AP region for left upper-lobe tumors, and to the subcarinal area for middle-and lower-lobe tumors. 18,20,24 -26,35 Previous studies suggest that survival is significantly worse in patients who have hilar or interlobar rather than only peribronchial lymph node involvement or that multiple levels of N1 nodal disease are associated with a worse outcome than single-level disease (Table  3) . We were unable to identify differences in outcome for patients with peripheral versus hilar N1 disease, but we found that survival was significantly worse in cases of multiple versus single levels of N1 nodal metastases.
Differences in nomenclature between the Naruke and the MD-ATS lymph node maps pose challenges for the analysis of an international database. Reconciliation of these maps is the subject of a separate study (which is being undertaken by the IASLC staging committee) and is, therefore, not discussed in detail here. Nevertheless, our exploratory analyses suggested that for the purposes of analyzing N stages, it was statistically appropriate to consolidate several lymph node stations from both mapping systems together into zones. This approach allowed us to address the findings of previous studies that skip metastases and single-level N2 disease are both associated with better survival rates than involvement of multiple N2 lymph node stations (Table 4 ). In contrast with previous studies, 36 -43 we were able to identify a better survival rate only for patients with left upper-lobe tumors with AP zone N2 disease-not for patients with right upper-lobe tumors with metastases confined to the superior mediastinum. These results should be interpreted with caution because the numbers of patients available for these subset analyses are relatively small. The most salient finding with respect to pN staging in our database is that patients fall into three prognostically distinct categories, depending on the extent of nodal metastases: single-zone N1, multiple-zone N1 or single-zone N2, and multiple-zone N2. In conjunction with our other analyses, these results suggest that the overall disease burden, rather than just the anatomical location of lymph node involvement, may have the most important influence on outcome. These three categories have not been clearly identified in previous studies (Table 3 and 4) , which have focused predominantly on comparing survival relative to varying levels of either N1 or N2 disease. Validating this finding in a way that would be statistically sound enough to warrant a change in the N descriptors for the staging system would clearly require a prospective study of even larger numbers of patients with meticulous pN staging. Nevertheless, our results provide the impetus for such a study and the rationale for stratifying patients according these three prognostic groups in clinical trials.
In summary, analyses of clinical and pathological N staging in the IASLC database support the continued use of the current N descriptors in the lung cancer database. Additional analyses suggest that consolidation of multiple lymph node stations into zones and stratification of patients into three groups according to the extent of nodal disease may be appropriate and warrant inclusion in future studies.
